A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites.

Trial Profile

A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Malignant ascites
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2011 Planned end date changed from 1 Sep 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 05 Apr 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 03 Oct 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top